Naturgy Energy Group, S.A. NTGY

Sociedad Química y Minera de Chile: Stock Snapshot After Recent Moves Sociedad Química y Minera de Chile (NYSE:SQM) has drawn fresh attention after recent price swings, with the stock closing at US$64.87 and showing mixed returns across the past month and past 3 months. Recent trading has been heavy on the brakes, with Sociedad Química y Minera de Chile’s share price down 6.1% over the past week and 17.9% over the past month. However, the 1 year total shareholder return of 52.0% and 5 year...

STUTTGART, GERMANY - September 30, 2026 (NEWMEDIAWIRE) - The Supervisory Board of CENIT Aktiengesellschaft constituted itself today following the court's appointment of Klaus Weinmann and Uwe Kemm. The two Supervisory Board members were appointed...

French government bond yields are back in the spotlight, and the ripple effects are running through banks, insurers and blue-chip borrowers across the euro area. When sovereign risk climbs, attention often shifts to high-quality corporate credit, where balance sheets can look steadier than the state. This article explores that shift and reveals 3 large European stocks exposed to this news, helping you judge whether they deserve space on your watchlist. The stocks highlighted below are just a...

Trade friction between China and Europe is turning supply chains into a live wire, and capital is already searching for companies that could benefit if sourcing shifts closer to home. That reshuffle risk cuts both ways, so investors who ignore it may miss important moves in some European stocks. This article walks through three stocks exposed to the latest EU China flare up and explains why the news matters for each one. The stocks covered below are a small sample of what this supply chain...

Lagardere (ENXTPA:MMB) has come back into focus after recent trading left the share price at €18.04, with the stock down over the past month and past 3 months. Short-term momentum for Lagardere looks weak, with the share price return down 4.1% over the past month and 7.8% over three months. The 5.7% three-year total shareholder return hints at a mixed, stop-start longer-term journey driven by shifting expectations around growth and risk. Scan other media and retail operators moving on similar...

About 50% of Concentrix’s revenue is coming from business it earned since introducing AI tools three years ago.

Russian strikes on Ukrainian data and telecom hubs have turned the resilience of European digital infrastructure from a dull utility story into a live risk test. For investors, that raises both potential opportunity and potential pitfalls as markets rethink how to price communications lifelines, cloud capacity and backbone networks. This article walks through three stocks exposed to these shocks and explores where the current stress might help or hurt their long term appeal. The stocks below...

Clean-Label Demand and Personal Care Innovation Drive Lemon Compound Opportunities as Sustainable Sourcing and Advanced Extraction Gain MomentumDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Lemon Compound Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The global lemon compound market was valued at USD 1.36 billion in 2025 and is projected to reach USD 2.24 billion by 2035, expanding at a compound annual grow

LUXEMBOURG, September 30, 2026--SES and Sky have extended their long-standing partnership in a new multi-year agreement for direct-to-home (DTH) satellite services across the United Kingdom and Republic of Ireland, running into the next decade.

Lagardere has slipped in recent months, yet over the past three years the stock is still modestly ahead. This puts fresh attention on whether today's share price lines up with the earnings that support it. With the share now at €18.04, the real issue for you as an investor is how much of the underlying profit story is already in the price. The stock has gained 5.7% over the past three years, so anyone looking at Lagardere today is effectively judging whether that medium term climb is fully...

ACEA has rewarded patient shareholders over recent years, yet the share price has been softer lately, which naturally raises the question of whether the current valuation is still well supported by its earnings power. For anyone looking at the stock today, the key issue is how much of the past share price gain already reflects what the business is earning right now. Over the past 3 years the share price has climbed 129.0%, which puts real pressure on the question of how fully its earnings...

Bayer has delivered a sharp share price recovery over the past year, which puts fresh attention on a simple question about the stock: Are investors now paying a price that still lines up with what the business generates in sales? Bayer’s 83.8% 1 year return puts a lot of recent optimism on trial against what the company’s revenue base can realistically support. New U.S. regulatory milestones for therapies like Lynkuet for vasomotor symptoms in breast cancer patients and KERENDIA for chronic...

AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Computer-Aided Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound

Charenton-le-Pont, 29 September 2026 Availability of the half-year financial report The Board of Directors of Marie Brizard Wine & Spirits approved the financial statements for the first half of 2026 at its meeting on 23 September 2026. The half-year financial report includes a half-year activity report, the consolidated half-year financial statements, the statutory auditors' report on the half-year financial statements and a statement by the person responsible for the half-year financial report

SAN DIEGO, September 29, 2026--Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.